Nature Communications (Feb 2022)
Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma
- Yuen Lam Dora Ng,
- Evelyn Ramberger,
- Stephan R. Bohl,
- Anna Dolnik,
- Christian Steinebach,
- Theresia Conrad,
- Sina Müller,
- Oliver Popp,
- Miriam Kull,
- Mohamed Haji,
- Michael Gütschow,
- Hartmut Döhner,
- Wolfgang Walther,
- Ulrich Keller,
- Lars Bullinger,
- Philipp Mertins,
- Jan Krönke
Affiliations
- Yuen Lam Dora Ng
- Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
- Evelyn Ramberger
- Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
- Stephan R. Bohl
- Department of Internal Medicine III, Ulm University Hospital
- Anna Dolnik
- Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
- Christian Steinebach
- Department of Pharmaceutical & Medicinal Chemistry, Pharmaceutical Institute, University of Bonn
- Theresia Conrad
- Experimentelle Pharmakologie & Onkologie (EPO) Berlin-Buch GmbH
- Sina Müller
- Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
- Oliver Popp
- Proteomics Platform, Max Delbrück Center for Molecular Medicine
- Miriam Kull
- Department of Internal Medicine III, Ulm University Hospital
- Mohamed Haji
- Proteomics Platform, Max Delbrück Center for Molecular Medicine
- Michael Gütschow
- Department of Pharmaceutical & Medicinal Chemistry, Pharmaceutical Institute, University of Bonn
- Hartmut Döhner
- Department of Internal Medicine III, Ulm University Hospital
- Wolfgang Walther
- Experimental and Clinical Research Center, Charité Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine
- Ulrich Keller
- Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
- Lars Bullinger
- Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
- Philipp Mertins
- Proteomics Platform, Max Delbrück Center for Molecular Medicine
- Jan Krönke
- Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
- DOI
- https://doi.org/10.1038/s41467-022-28515-1
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 13
Abstract
Acquired resistance to immunomodulatory drugs is common in multiple myeloma patients, but rarely attributed to genetic alterations. Here, proteomic, phosphoproteomic and RNA sequencing analysis in five paired pre-treatment and relapse samples reveals a CDK6-regulated protein resistance signature.
